Page 171 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 171

CHAPTER 10  Adrenoceptor Antagonist Drugs     157



                               HO
                                                                                CH 3

                                                     N                  O  CH 2  CH   CH 2  CH 2  CI  R 1  CH 2
                                          N   CH 2  C                              N                    N +  + CI –
                                                     N
                           H C                       H                          CH 2                 R 2   CH 2
                            3
                                        Phentolamine              Phenoxybenzamine              Active (ethyleneimonium)
                                                                                                     intermediate

                                                                                    O
                                                                  N
                                                  CH O                  N       N   C
                                                    3
                                                                                          O
                                                  CH O                N
                                                    3
                                                                  NH 2
                                                                     Prazosin
                                                                                             SO NH
                                                          O  CH 2  CH 2  NH  CH  CH 2          2  2
                                                                           CH 3
                                                          O  CH 2  CH 3                      O  CH 3
                                                                    Tamsulosin

                    FIGURE 10–1  Structure of several α-receptor–blocking drugs.



                    Phenoxybenzamine forms a reactive ethyleneimonium intermedi-  of agonists with both α and β  effects (eg, epinephrine), selec-
                                                                                                 2
                    ate (Figure 10–1) that covalently binds to α receptors, resulting   tive  α-receptor antagonism may convert a pressor to a depres-
                    in  irreversible  blockade.  Figure  10–2  illustrates  the  effects  of  a   sor response (Figure 10–3).  This change in response is called
                    reversible drug in comparison with those of an irreversible agent.  epinephrine reversal; it illustrates how the activation of both α
                       As discussed in Chapters 1 and 2, the duration of action of   and β receptors in the vasculature may lead to opposite responses.
                    a reversible antagonist is largely dependent on the half-life of   Alpha-receptor antagonists often cause orthostatic hypoten-
                    the drug in the body and the rate at which it dissociates from   sion and reflex tachycardia; nonselective (α  = α , Table 10–1)
                                                                                                               2
                                                                                                          1
                    its receptor: The shorter the half-life of the drug in the body,   blockers usually cause significant tachycardia if blood pressure is
                    the less time it takes for the effects of the drug to dissipate. In   lowered below normal. Orthostatic hypotension is due to antago-
                    contrast, the effects of an irreversible antagonist may persist long   nism of sympathetic nervous system stimulation of α  receptors
                                                                                                                  1
                    after the drug has been cleared from the plasma. In the case of   in vascular smooth muscle; contraction of veins is an important
                    phenoxybenzamine, the restoration of tissue responsiveness after   component of the normal capacity to maintain blood pressure
                    extensive α-receptor blockade is dependent on synthesis of new   in the upright position since it decreases venous pooling in the
                    receptors, which may take several days.  The rate of return of   periphery. Constriction of arterioles in the legs also contributes to
                      -adrenoceptor responsiveness may be particularly important in   the normal orthostatic response. Tachycardia may be more marked
                    α 1
                    patients who have a sudden cardiovascular event or who become   with agents that block α -presynaptic receptors in the heart, since
                                                                                           2
                    candidates for urgent surgery.                       the augmented release of norepinephrine will further stimulate
                                                                         β receptors in the heart.
                    Pharmacologic Effects

                    A.  Cardiovascular Effects                           B.  Other Effects
                    Because arteriolar and venous tone are determined to a large   Blockade of  α receptors in other tissues elicits miosis (small
                    extent by  α receptors on vascular smooth muscle,  α-receptor   pupils) and nasal stuffiness. Alpha 1  receptors are expressed in the
                    antagonist drugs cause a lowering of peripheral vascular resistance   base of the bladder and the prostate, and their blockade decreases
                    and blood pressure (Figure 10–3). These drugs can prevent the   resistance to the flow of urine. Alpha blockers, therefore, are
                    pressor effects of usual doses of α agonists; indeed, in the case   used therapeutically for the treatment of urinary retention due
   166   167   168   169   170   171   172   173   174   175   176